THE IMPACT OF SEX HORMONE LEVELS ON COGNITIVE FUNCTIONING IN WOMEN WITH SCHIZOPHRENIA - SCOPING REVIEW.

4区 医学 Q2 Medicine
Psychiatria Danubina Pub Date : 2025-09-01
Krzysztof Krysta, Beata Tredzbor, Ewa Martyniak, Agnieszka Kozmin-Burzynska, Katarzyna Piekarska-Bugiel, Roman Wojnar, Rafal Bies, Marek Krzystanek
{"title":"THE IMPACT OF SEX HORMONE LEVELS ON COGNITIVE FUNCTIONING IN WOMEN WITH SCHIZOPHRENIA - SCOPING REVIEW.","authors":"Krzysztof Krysta, Beata Tredzbor, Ewa Martyniak, Agnieszka Kozmin-Burzynska, Katarzyna Piekarska-Bugiel, Roman Wojnar, Rafal Bies, Marek Krzystanek","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cognitive impairment is a core and disabling feature of schizophrenia, with a profound impact on functional outcomes. Female patients often demonstrate better cognitive profiles than males, suggesting a potential modulatory role of sex hormones. Estrogens, particularly estradiol, have been hypothesized to exert neuroprotective effects via modulation of neurotrophic, neurotransmitter, and inflammatory pathways. However, evidence regarding the relationship between sex hormone levels and cognition in schizophrenia remains scattered and inconclusive.</p><p><strong>Methods: </strong>This scoping review synthesized evidence from clinical and preclinical studies examining the association between endogenous estrogen levels or estrogen-based treatments and cognitive functioning in women with schizophrenia. We included peer-reviewed literature addressing hormonal fluctuations across the menstrual cycle, menopause, and in response to antipsychotic treatment, with specific focus on estradiol and selective estrogen receptor modulators.</p><p><strong>Results: </strong>Findings suggest that low estrogen levels may be linked to more severe negative symptoms and poorer cognitive performance in female patients. Studies investigating menstrual cycle phases report mixed results, while evidence from animal models indicates potential cognitive benefits of estrogenic compounds. Raloxifene has shown promise in mitigating cognitive deficits when administered during sensitive developmental periods. However, large-scale hormonal interventions in postmenopausal women have produced inconsistent results, likely due to differences in timing, dosage, and individual neurobiological context.</p><p><strong>Conclusions: </strong>Sex hormone levels, especially estradiol, appear to influence cognitive outcomes in women with schizophrenia, though findings are heterogeneous. Future research should address methodological inconsistencies and explore phase-specific, personalized hormonal strategies. A deeper understanding of hormonal-cognitive interactions may inform more effective, sex-sensitive treatment approaches in schizophrenia.</p>","PeriodicalId":20760,"journal":{"name":"Psychiatria Danubina","volume":"37 Suppl 1","pages":"154-159"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatria Danubina","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cognitive impairment is a core and disabling feature of schizophrenia, with a profound impact on functional outcomes. Female patients often demonstrate better cognitive profiles than males, suggesting a potential modulatory role of sex hormones. Estrogens, particularly estradiol, have been hypothesized to exert neuroprotective effects via modulation of neurotrophic, neurotransmitter, and inflammatory pathways. However, evidence regarding the relationship between sex hormone levels and cognition in schizophrenia remains scattered and inconclusive.

Methods: This scoping review synthesized evidence from clinical and preclinical studies examining the association between endogenous estrogen levels or estrogen-based treatments and cognitive functioning in women with schizophrenia. We included peer-reviewed literature addressing hormonal fluctuations across the menstrual cycle, menopause, and in response to antipsychotic treatment, with specific focus on estradiol and selective estrogen receptor modulators.

Results: Findings suggest that low estrogen levels may be linked to more severe negative symptoms and poorer cognitive performance in female patients. Studies investigating menstrual cycle phases report mixed results, while evidence from animal models indicates potential cognitive benefits of estrogenic compounds. Raloxifene has shown promise in mitigating cognitive deficits when administered during sensitive developmental periods. However, large-scale hormonal interventions in postmenopausal women have produced inconsistent results, likely due to differences in timing, dosage, and individual neurobiological context.

Conclusions: Sex hormone levels, especially estradiol, appear to influence cognitive outcomes in women with schizophrenia, though findings are heterogeneous. Future research should address methodological inconsistencies and explore phase-specific, personalized hormonal strategies. A deeper understanding of hormonal-cognitive interactions may inform more effective, sex-sensitive treatment approaches in schizophrenia.

性激素水平对女性精神分裂症患者认知功能的影响——范围综述。
背景:认知障碍是精神分裂症的核心和致残特征,对功能预后有深远影响。女性患者通常表现出比男性更好的认知特征,这表明性激素可能起到调节作用。雌激素,特别是雌二醇,已被假设通过调节神经营养、神经递质和炎症途径发挥神经保护作用。然而,关于精神分裂症患者性激素水平与认知之间关系的证据仍然分散且不确定。方法:本综述综合了来自临床和临床前研究的证据,研究了内源性雌激素水平或雌激素治疗与精神分裂症女性认知功能之间的关系。我们纳入了同行评议的文献,讨论了月经周期、更年期和抗精神病治疗对激素波动的影响,特别关注雌二醇和选择性雌激素受体调节剂。结果:研究结果表明,低雌激素水平可能与女性患者更严重的阴性症状和更差的认知表现有关。调查月经周期阶段的研究报告了不同的结果,而来自动物模型的证据表明雌激素化合物可能对认知有好处。雷洛昔芬在敏感的发育时期有减轻认知缺陷的前景。然而,绝经后妇女的大规模激素干预产生了不一致的结果,可能是由于时间、剂量和个体神经生物学背景的差异。结论:性激素水平,尤其是雌二醇,似乎会影响女性精神分裂症患者的认知结果,尽管研究结果不尽相同。未来的研究应该解决方法上的不一致,并探索阶段性的、个性化的激素策略。对激素-认知相互作用的更深入了解可能会为精神分裂症提供更有效、性别敏感的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Psychiatria Danubina
Psychiatria Danubina 医学-精神病学
CiteScore
3.00
自引率
0.00%
发文量
288
审稿时长
4-8 weeks
期刊介绍: Psychiatria Danubina is a peer-reviewed open access journal of the Psychiatric Danubian Association, aimed to publish original scientific contributions in psychiatry, psychological medicine and related science (neurosciences, biological, psychological, and social sciences as well as philosophy of science and medical ethics, history, organization and economics of mental health services).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信